Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jonathan Schouest

Rheumatology Lacombe, LA Medical Doctor

NPI 1972007714 CMS profile 11389149

64301 Highway 434, Lacombe, LA 70445

Open in the dashboard

General payments

$8,232

362 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Schouest of Lacombe, LA is reported in the CMS Open Payments database as having received $8,232 across 362 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,404 175
2024 General $3,461 154
2023 General $1,142 31
2022 General $225 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Schouest
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Jonathan Schouest were reported at $3,404. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Jonathan Schouest Rheumatology median Middle half National median
2019 $0 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $225 $627 $125–$2,303 $149
2023 $1,142 $741 $145–$2,524 $160
2024 $3,461 $830 $166–$2,660 $164
2025 $3,404 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $2,952 118 payments
  2. Amgen Inc. $1,472 79 payments
  3. UCB, Inc. $620 30 payments
  4. Mallinckrodt Hospital Products Inc. $509 14 payments
  5. Janssen Biotech, Inc. $496 22 payments
  6. Pfizer Inc. $366 18 payments
  7. ANI Pharmaceuticals, Inc. $310 16 payments
  8. Nevro Corp. $173 3 payments
  9. Biogen, Inc. $155 7 payments
  10. Novartis Pharmaceuticals Corporation $118 5 payments
  11. Other $1,060 50 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $8,052 360 payments
  2. Education $180 2 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $1,842 80 payments
  2. SKYRIZI Immunology $573 15 payments
  3. KRYSTEXXA $546 28 payments
  4. ACTHAR $509 14 payments
  5. TREMFYA $426 18 payments
  6. Enbrel $397 19 payments
  7. Otezla $379 23 payments
  8. XELJANZ $366 18 payments
  9. SKYRIZI Immunology $314 11 payments
  10. PURIFIED CORTROPHIN GEL $310 16 payments
  11. Other $3,078 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$67,913

Of which drugs: $745

Medicare patients

243

Average age 72

Services billed

1,195

186 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 31%
Depression 28%
Diabetes 24%
Chronic kidney disease 23%
Osteoporosis 23%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$689 15 —
KRYSTEXXA
$365 — —
SKYRIZI
$331 — —
ACTHAR
$204 — —
Cimzia
$203 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

362 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record